Panacea Biotec Q3 FY26: 9M revenue up 25 percent, losses persist

Going-concern doubtExceptional itemRevenue growth above 20%Net loss reportedResults View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹351.90

prior close

₹359.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+2.2% vs market

Pharmaceuticals peers, median of 157sector-0.7%+2.3% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-1.1

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7-0.5+2.2-0.7+2.3

Next day

-1.5-2.0+0.5-1.4-0.1

-1.4-2.7+1.3-2.1+0.7

+2.0-1.7+3.7-1.6+3.7

-0.3-1.4+1.1-1.6+1.3

-1.8-2.8+1.0-2.5+0.6

-3.7-2.8-0.9-2.9-0.8

15d

-9.2-8.4-0.8-6.3-2.9

-2.8-9.1+6.3-6.6+3.8

-5.5-4.0-1.5-3.3-2.2

+4.4+2.6+1.8+0.7+3.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec reported Q3 FY26 standalone revenue of Rs 99.31 crore with a net loss of Rs 7.36 crore versus a Rs 9.65 crore profit YoY. Nine month standalone revenue rose 25 percent to Rs 302.37 crore, but losses widened to Rs 29.70 crore. Consolidated Q3 revenue was Rs 165.19 crore with a small PAT of Rs 3.89 crore. An exceptional income of Rs 16.79 crore was recognized from an Apotex settlement and deferred brand consideration. Management reiterated going concern basis citing higher vaccine orders.

Likely market impact

Standalone losses continue despite revenue growth. Exceptional items and settlement income supported consolidated numbers. Going concern flag remains.